Trials / Completed

CompletedNCT03871790

Peptide-based Immunization for Colon- and and Pancreas-carcinoma

Peptide-based Immunization for Colon- and Pancreas-carcinoma (PICOP-GLOBAL): An International, Multicenter Protocol

Status: Completed
Phase: —
Study type: Observational
Enrollment: 50 (actual)

Sponsor: CENTOGENE GmbH Rostock · Industry
Sex: All
Age: 18 Years
Healthy volunteers: —

Summary

An international, multicenter study to identify tumor molecular particularities and neoepitopes among participants with colorectal and pancreatic tumors undergoing surgery.

Detailed description

Colorectal and pancreatic cancers are among the most common causes of cancer-related death over the world. Standard of care treatment for colon and pancreas cancer is stage dependent and includes surgical, chemotherapeutic, and radiation therapy. However, the current statistics underlines an urgent need for improved treatment. Patient-individualized treatments and enhancement of the immune response via vaccination are among new therapeutic options. The enhancement of the immune response via vaccination is among new therapeutic options. Here, either cell-specific antigens, over-expressed tumor specific antigens or mutated tumor-specific antigens (neoepitopes) can be employed. Especially the latter possess the biggest potential for high specificity but presuppose an extensive characterization of the respective tumor. In order to identify a neoepitope-based vaccination approach for patient-individualized treatment options the molecular particularities of tumors have to be analysed. The aim of this study is to identify tumor molecular particularities and neoepitopes among patients with colorectal and pancreatic tumors undergoing surgery.

Conditions

Timeline

Start date: 2019-04-01
Primary completion: 2022-04-01
Completion: 2022-08-31
First posted: 2019-03-12
Last updated: 2023-02-10

Locations

1 site across 1 country: Pakistan

Source: ClinicalTrials.gov record NCT03871790. Inclusion in this directory is not an endorsement.